TL;DR: Cannabis equities finished Friday, June 26 near session highs as the MSOS ETF extended its best weekly performance of 2026, buoyed by a second constructive day of DEA administrative rescheduling hearings. With the holiday-shortened week of June 29 ahead, investors will focus on rescheduling timeline developments, imminent Q2 earnings prints from top MSOs, and whether technical breakout levels hold.
End-of-Day Market Snapshot: June 26
Cannabis stocks closed Friday in broadly positive territory after a week dominated by two major developments: the commencement of DEA administrative law hearings on full cannabis rescheduling, and a series of company-level catalysts that reaffirmed sector operational momentum.
The AdvisorShares Pure US Cannabis ETF (MSOS) posted its highest weekly close since early 2024, with institutional flows remaining constructive through the session. Volume was elevated relative to the 90-day average — a reliable indicator that institutional participation is deepening rather than thinning as the sector tests multi-year resistance.
On the individual stock front, Green Thumb Industries (GTBIF) and Curaleaf Holdings (CURLF) held gains after delivering newsflow that reinforced their positions as the sector two largest free cash flow generators. Curaleaf shareholders earlier in the week approved a Delaware redomicile that clears a structural barrier to U.S. exchange uplisting — a move that could meaningfully expand the accessible investor pool if major exchange approval follows. Track real-time performance of these and other cannabis equities at the cannabis stock tracker.
Organigram Holdings (OGI) outperformed among Canadian licensed producers on the strength of its BAT partnership and expanding EU medical footprint. Tilray Brands (TLRY), fresh off record Q3 FY2026 international cannabis revenue, held prior gains into the close.
The Rescheduling Hearing Storyline
Day 2 of the DEA administrative hearings on cannabis rescheduling concluded without adverse procedural developments — a net positive for sector sentiment. The hearings, which opened Thursday, June 25, represent the final major regulatory hurdle before an administrative law judge submits a recommended ruling to the DEA Administrator.
The critical distinction entering next week: these hearings have shifted in scope. While the original rescheduling proposal moved cannabis to Schedule III — which would have provided partial 280E relief — testimony this week introduced arguments for Schedule II or further reclassification that could unlock full 280E elimination for qualifying operators.
For MSO operators, the financial stakes are substantial. Green Thumb Industries has guided that complete 280E elimination would add approximately $80 to $100 million in annual after-tax cash flow at current revenue run rates. Curaleaf and Trulieve Cannabis (TCNNF) would see comparable improvements. The market is increasingly pricing in a favorable outcome, but the timeline to a final DEA ruling remains the key variable — most likely Q3 or Q4 2026 based on current hearing pace.
What to Watch: Week of June 29
The upcoming trading week carries a compressed calendar — U.S. markets observe Independence Day on Friday, July 4, making it a four-session week. Several catalysts are worth monitoring:
Earnings cadence: Green Thumb Industries reports Q2 2026 results in mid-July, but pre-announcement commentary or guidance updates via investor relations channels are possible ahead of the holiday. Investors should monitor whether any MSO introduces forward guidance revisions in light of rescheduling hearing developments.
Rescheduling procedural updates: The DEA administrative law judge process is not publicly livestreamed, but party filings and procedural orders remain publicly accessible. Any indication of an accelerated or decelerated ruling timeline will move the sector.
Technical levels to watch: MSOS has established a clear pattern of higher highs and higher lows since the January 2026 low. The zone between $12.50 and $13.50 represents significant multi-year overhead supply; a sustained close above this band on elevated volume would represent a technical confirmation of trend change. Failure to hold recent support near $11.80 would signal the breakout attempt has stalled.
Canadian LP performance: OGI and TLRY both carry event-driven catalysts into Q3 — BAT partnership milestones and international medical expansion respectively. European cannabis legalization progress in Germany and the Netherlands continues to create incremental demand for export-grade medical product.
Conclusion: A Sector at a Structural Inflection
Friday close captures a cannabis sector that has materially re-rated in 2026, driven by genuine regulatory progress rather than speculative sentiment. The rescheduling hearing process — while procedurally complex — is running on an orderly timeline, and the market appears to be pricing a favorable, if not maximally bullish, outcome.
For investors, the week of June 29 offers a window to assess whether the sector can sustain its breakout or whether participants use the holiday week to take partial profits. The balance of evidence — institutional flows, improving fundamentals, advancing regulatory clarity — continues to favor the former. Monitor key names like CURLF, GTBIF, TCNNF, OGI, and TLRY for early signals of which direction the sector resolves heading into Q3 earnings season.